Results 211 to 220 of about 172,791 (358)

PUVA treatment of psoriasis. [PDF]

BMJ, 1978
D Hyatt, M Whitefield, H R Hudson
openaire   +5 more sources

Case Report of a Patient With Psoriasis Vulgaris, Psoriatic Arthritis and Alopecia Universalis Successfully Treated With Tofacitinib and Methotrexate

JEADV Clinical Practice, EarlyView.
We present a case of a 31‐year‐old female with alopecia universalis, psoriasis vulgaris, and psoriatic arthritis, who showed poor response to prior treatments. Following the initiation of a combination therapy with tofacitinib and methotrexate, significant improvements in joint pain and hair regrowth were observed.
Jan Nicolai Wagner, Matthias Augustin, Caroline Gewiss, Carolin Grote, Nesrine Ben‐Anaya   +4 more
wiley   +1 more source

Therapeutic Potential of Curcumin and Novel Formulations in Psoriasis Treatment: Evidence and Future Prospects. [PDF]

Drug Des Devel Ther
Kantasa T, Yeerong K, Klinjan P, Na Takuathung M, Settakorn K, Chuamanochan M, Tovanabutra N, Ampasavate C, Koonrungsesomboon N.   +8 more
europepmc   +1 more source

Single-atom catalysts-based catalytic ROS clearance for efficient psoriasis treatment and relapse prevention via restoring ESR1. [PDF]

Nat Commun, 2023
Lu X, Kuai L, Huang F, Jiang J, Song J, Liu Y, Chen S, Mao L, Peng W, Luo Y, Li Y, Dong H, Li B, Shi J.   +13 more
europepmc   +1 more source

Commentary on Oral Methoxsalen Photochemotherapy for the Treatment of Psoriasis: A Cooperative Clinical Trial: From Napkin Notes to Notabilia

, 1989
Jeffrey D. Bernhard
openalex   +1 more source

Combination treatment seems rarely to be used in psoriasis [PDF]

, 2000
D. Cullington
openalex   +1 more source

Efficacy and Tolerability of Brodalumab in 42 Adult Patients With Moderate to Severe Psoriasis: First French Real‐Life Case Series on Hard‐to‐Treat Areas

JEADV Clinical Practice, EarlyView.
In our real‐life study, brodalumab demonstrates clinical efficacy on psoriasis lesions over a median duration of treatment of 4 months, associated with mean reductions of 94.3% for BSA, 93.1% for PASI and 88.0% for PGA. 23 patients no longer had a single lesion at the follow‐up visit.
Marc Perrussel, Bruno Sassolas
wiley   +1 more source

A triple-targeting "nano-brake" remodeling the impaired immune microenvironment in skin lesions for psoriasis treatment. [PDF]

Mater Today Bio
Chen R, Duan B, Li S, Zhu Y, Huang Z, Shen D, Ye Z, Yan Y, Qiu C, Guan H, Yao Y, Dong J, Wu F, Jiang X, Shi X, Kou L.   +15 more
europepmc   +1 more source

Inhibition of NLRP3 Inflammasome Activation by 3H-1,2-Dithiole-3-Thione: A Potential Therapeutic Approach for Psoriasis Treatment. [PDF]

Int J Mol Sci, 2023
Shih MC, Li CL, Liao EC, Yen CY, Yen LJ, Wang KC, Lu LY, Chou TY, Chen YC, Yu SJ.   +9 more
europepmc   +1 more source

Etanercept in the treatment of psoriatic arthritis and psoriasis [PDF]

, 2000
Kazuki Takada
openalex   +1 more source